• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings

    6/6/24 12:22:51 PM ET
    $ASNS
    $FRGT
    $ICU
    $LULU
    Telecommunications Equipment
    Telecommunications
    Professional Services
    Consumer Discretionary
    Get the next $ASNS alert in real time by email

    U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Thursday.

    The Dow traded up 0.14% to 38,860.40 while the NASDAQ fell 0.07% to 17,175.73. The S&P 500 also rose, gaining, 0.01% to 5,354.33.

    Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields

    Leading and Lagging Sectors

    Consumer discretionary shares rose by 0.5% on Thursday.

    In trading on Thursday, utilities shares fell by 0.5%.

    Top Headline

    Lululemon Athletica Inc. (NASDAQ:LULU) reported upbeat financial results for its first quarter and authorized a $1 billion increase in its stock repurchase program on Wednesday.

    The company said it sees second-quarter revenue in the range of $2.4 billion to $2.42 billion versus estimates of $2.45 billion. The company anticipates second-quarter earnings of $2.92 to $2.97 per share versus estimates of $3.01 per share.

    Equities Trading UP
                           

    • Replimune Group, Inc. (NASDAQ:REPL) shares shot up 27% to $7.07 as the company announced positive topline primary analysis data by Independent Central Review from IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma.
    • Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) got a boost, surging 26% to $6.35 after Cycle Pharmaceuticals confirmed that it made a proposal to buy the company.
    • Freight Technologies, Inc. (NASDAQ:FRGT) shares were also up, gaining 94% to $1.2196 after the company said it added 26 new customers and 149 new carriers in 2024.

    Equities Trading DOWN

    • Actelis Networks, Inc. (NASDAQ:ASNS) shares dropped 38% to $2.3001 after the company announced an agreement for the immediate exercise of certain outstanding warrants for gross proceeds of $3 million.
    • Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) were down 33% to $0.2371. SeaStar Medical announced a 25-for-1 reverse stock split.
    • Ventyx Biosciences, Inc. (NASDAQ:VTYX) was down, falling 28% to $3.8050 after the company announced preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models.

    Also Check This Out: Top 4 Industrials Stocks That Could Lead To Your Biggest Gains This Quarter

    Commodities

    In commodity news, oil traded up 2.1% to $75.63 while gold traded up 0.3% at $2,383.00.

    Silver traded up 2.1% to $30.71 on Thursday, while copper rose 1% to $4.6525.

    Euro zone

    European shares were higher today. The eurozone's STOXX 600 rose 0.58%, Germany's DAX gained 0.30% and France's CAC 40 rose 0.41%. Spain's IBEX 35 Index rose 0.60%, while London's FTSE 100 rose 0.31%.

    The ECB cut the three key interest rates by 25 basis points, in line with market estimates. Retail sales in the Eurozone fell 0.5% month-over-month in April compared to revised 0.7% gain in March, while Eurozone construction PMI increased to 42.9 in May from 41.9 in the prior month.

    The S&P Global UK construction PMI climbed to 54.7 in May, recording the highest level since May 2022, while The France construction PMI increased to 43.4 in May from 41.5 a month ago. Factory orders in Germany fell by 0.2% month-over-month for April.

    Asia Pacific Markets

    Asian markets closed mostly higher on Thursday, with Japan's Nikkei gaining 0.55%, China's Composite Index falling 0.54%, Hong Kong's Hang Seng Index gaining 0.28% and India's S&P BSE Sensex gaining 0.7%.

    Australia’s trade surplus on goods increased to AUD 6.55 billion in April 2024 compared to a revised AUD 4.84 billion surplus in the prior month. Exports of goods from Australia fell 2.5% to a 28-month low level of AUD 43.32 billion in April, while imports of goods dipped by 7.2% to a three-month low level of AUD 36.77 billion.

    Economics

    • U.S. initial jobless claims rose by 8,000 to 229,000 in the week ending June 1, compared to market estimates of 220,000.
    • The trade deficit in the U.S. increased to $74.6 billion in April versus a revised $68.6 billion gap in March.
    • Unit labor costs in the nonfarm business sector rose by an annualized 4% in the first quarter compared to a revised 2.8% fall in the previous period.
    • Nonfarm business sector labor productivity increased by 0.2% in the first quarter compared to preliminary reading of a 0.3% gain.
    • U.S. natural-gas supplies increased 98 billion cubic feet during the week ended May 31, compared to market estimates of an 89 billion cubic feet gain.

    Now Read This: Alphabet, Walmart And 2 Other Stocks Insiders Are Selling

    Get the next $ASNS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASNS
    $FRGT
    $ICU
    $LULU

    CompanyDatePrice TargetRatingAnalyst
    lululemon athletica inc.
    $LULU
    1/8/2026Hold
    Deutsche Bank
    lululemon athletica inc.
    $LULU
    12/12/2025$170.00Underperform → Hold
    Jefferies
    lululemon athletica inc.
    $LULU
    12/12/2025$200.00 → $215.00Market Perform
    Telsey Advisory Group
    lululemon athletica inc.
    $LULU
    12/10/2025Neutral
    Guggenheim
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    Ventyx Biosciences Inc.
    $VTYX
    11/5/2025$18.00Neutral → Buy
    H.C. Wainwright
    Replimune Group Inc.
    $REPL
    11/3/2025$11.00Underperform → Market Perform
    BMO Capital Markets
    Replimune Group Inc.
    $REPL
    10/27/2025$12.00Neutral → Buy
    H.C. Wainwright
    More analyst ratings

    $ASNS
    $FRGT
    $ICU
    $LULU
    SEC Filings

    View All

    Actelis Networks Inc. filed SEC Form 8-K: Other Events

    8-K - ACTELIS NETWORKS INC (0001141284) (Filer)

    2/11/26 4:15:54 PM ET
    $ASNS
    Telecommunications Equipment
    Telecommunications

    Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

    2/11/26 4:05:22 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Actelis Networks Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - ACTELIS NETWORKS INC (0001141284) (Filer)

    2/6/26 5:00:36 PM ET
    $ASNS
    Telecommunications Equipment
    Telecommunications

    $ASNS
    $FRGT
    $ICU
    $LULU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

    2/11/26 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    lululemon Introduces Unrestricted Power™ — A New Sensation for Strength Training

    Unrestricted Power features a new proprietary fabric innovation and performance-led design to deliver an unmatched combination of support, mobility, and on-body feel The training assortment was developed with lululemon Ambassadors, including Lewis Hamilton & Kayla Jeter lululemon (NASDAQ:LULU) today unveiled Unrestricted Power™, a new innovation platform engineered for heavy lifts and demanding gym sessions. The assortment, which launches this morning in North America, is backed by thousands of hours of research and development, providing secure support without compromising comfort and mobility, enabling a distraction-free fit built to match every move. This press release features mult

    2/10/26 8:30:00 AM ET
    $LULU
    Apparel
    Consumer Discretionary

    SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

    Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today the publication of early post-approval clinical experience from the use of the QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the prestigious, peer-reviewed journal Pediatric Nephrology. The publication, co-authored by leading experts including Stuart Goldstein, Kelli Krallman, Meredith Harris, Rajit Basu, David Askenazi, Shina Menon, Ma

    2/9/26 8:20:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ASNS
    $FRGT
    $ICU
    $LULU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Deutsche Bank initiated coverage on lululemon athletica

    Deutsche Bank initiated coverage of lululemon athletica with a rating of Hold

    1/8/26 10:59:22 AM ET
    $LULU
    Apparel
    Consumer Discretionary

    lululemon athletica upgraded by Jefferies with a new price target

    Jefferies upgraded lululemon athletica from Underperform to Hold and set a new price target of $170.00

    12/12/25 8:37:05 AM ET
    $LULU
    Apparel
    Consumer Discretionary

    Telsey Advisory Group reiterated coverage on lululemon athletica with a new price target

    Telsey Advisory Group reiterated coverage of lululemon athletica with a rating of Market Perform and set a new price target of $215.00 from $200.00 previously

    12/12/25 8:16:51 AM ET
    $LULU
    Apparel
    Consumer Discretionary

    $ASNS
    $FRGT
    $ICU
    $LULU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Van Heel Kenneth was granted 3,000 shares, increasing direct ownership by 61% to 7,940 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    2/10/26 4:58:51 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Neuman John was granted 3,000 shares, increasing direct ownership by 33% to 12,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    2/10/26 4:58:22 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Baird Jennifer A was granted 3,000 shares, increasing direct ownership by 83% to 6,620 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    2/10/26 4:57:09 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ASNS
    $FRGT
    $ICU
    $LULU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baird Jennifer A bought $987 worth of shares (4,200 units at $0.24), increasing direct ownership by 13% to 36,200 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/22/25 6:55:38 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Messinger Michael bought $5,098 worth of shares (14,500 units at $0.35), increasing direct ownership by 483% to 17,500 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    12/11/25 6:49:59 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Director Van Heel Kenneth bought $30,812 worth of shares (35,000 units at $0.88), increasing direct ownership by 243% to 49,400 units (SEC Form 4)

    4 - SeaStar Medical Holding Corp (0001831868) (Issuer)

    8/28/25 5:28:58 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ASNS
    $FRGT
    $ICU
    $LULU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASNS
    $FRGT
    $ICU
    $LULU
    Leadership Updates

    Live Leadership Updates

    View All

    La Rosa Holdings Corp. Announces Appointment of Nicholas Adler as Chairman of the Board and Chairman of the Compensation Committee

    Celebration, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) ("La Rosa" or the "Company"), a real estate and PropTech company, today announced that the Company's Board of Directors (the "Board") has appointed Mr. Nicholas Adler as a member of the Board, effective December 29, 2025. Upon his appointment, Mr. Adler was also named Chairman of the Board, Chairman of the Compensation Committee, and a member of both the Audit Committee and the Nominating and Corporate Governance Committee. Additionally, on December 29, 2025, Mr. Siamack Alavi notified the Board of his resignation as a director of the Company, effective immediately. Mr. Alavi also stepped down from hi

    12/30/25 8:30:00 AM ET
    $FRGT
    $LRHC
    Professional Services
    Consumer Discretionary
    Real Estate
    Finance

    Freight Technologies Announces the Commercial Launch of Zayren - AI-Powered Freight Rate Prediction & Carrier Matching Platform

    HOUSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Freight Technologies, Inc. (NASDAQ:FRGT, "Fr8Tech" or the "Company")), a logistics management innovation company offering a diverse portfolio of technology-driven solutions, today announced the commercial launch of Zayren, an artificial intelligence ("AI") based, machine learning pricing-prediction tool and carrier-matching platform designed specifically for cross-border and domestic over-the-road ("OTR") freight shipments across Mexico and the United States. Developed by Fr8Tech's in-house AI Lab or the Artificial Intelligence Lab, Zayren provides real-time freight-rate predictions, enabling shippers and brokers to access instant pricing insight

    11/19/25 9:00:00 AM ET
    $FRGT
    Professional Services
    Consumer Discretionary

    SeaStar Medical Announces Appointment of Michael Messinger as CFO

    DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer. "Mike brings to SeaStar Medical a breadth of financial expertise, operational discipline, and strategic healthcare experience that will be invaluable as we grow our commercial operations and prepare for additional commercial opportunities for our SCD therapy," stated Eric Schlorff, CE

    11/17/25 8:43:00 AM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    $ASNS
    $FRGT
    $ICU
    $LULU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ventyx Biosciences Inc.

    SC 13G/A - Ventyx Biosciences, Inc. (0001851194) (Subject)

    11/14/24 7:54:08 PM ET
    $VTYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by SeaStar Medical Holding Corporation

    SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)

    11/14/24 5:35:52 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Replimune Group Inc.

    SC 13G/A - Replimune Group, Inc. (0001737953) (Subject)

    11/14/24 4:20:10 PM ET
    $REPL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASNS
    $FRGT
    $ICU
    $LULU
    Financials

    Live finance-specific insights

    View All

    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

    2/11/26 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

    Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 11, 2026, during which management will discuss the fourth quarter and full year 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international

    2/4/26 6:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annual Changes to the Nasdaq-100 Index®

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, December 22, 2025. The following six companies will be added to the Index: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Ferrovial SE (NASDAQ:FER), Insmed Incorporated (NASDAQ:INSM), Monolithic Power Systems, Inc. (NASDAQ:MPWR), Seagate Technology Holdings plc (NASDAQ:STX), Western Digital Corp. (NASDAQ:WDC). The Nasdaq-100 Index is a globally recognized index that tracks the performance of 100 of the largest non-financial companies listed on the Nasdaq Stock Market® encompassi

    12/12/25 8:00:00 PM ET
    $ALNY
    $BIIB
    $CDW
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Retail: Computer Software & Peripheral Equipment